金威醫療(08143.HK)出售整形醫院之持股
金威醫療(08143.HK)公布,全資附屬康匯國際出售目標公司悅天投資股份,作價1,100萬元。
目標公司主要持有嘉興醫院,而嘉興醫院主要從事整形手術業務。
公司預期,出售事項錄虧損1,531萬元。公司指,醫院已1月份搬遷至嘉興市南湖區,相信將令嘉興醫院獲取高端客戶市場,預期產生較高毛利率,但因新進駐,須建立新的客戶基礎,並推出各種市場推廣活動。而在新冠肺炎爆發,有關市場推廣活動已全部暫停,對於早期並無穩固客戶基礎之嘉興醫院之表現產生重大影響,估算2月份之虧損為300萬元人民幣,料虧損需持續至疫情完結,為避免嘉興醫院的進一步虧損,退出計劃將對集團有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.